Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05009992 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy for the Treatment of Diffuse Midline Gliomas
A Phase 2 study of Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma, H3 K27M-Mutant, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT05009992: Recruiting Phase 2 study of Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma, H3 K27M-Mutant, sponsored by University of California, San Francisco.
NCT05009992 is a Phase 2 study of Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma, H3 K27M-Mutant that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 360 participants, above the 122-participant average among 28 other Diffuse Intrinsic Pontine Glioma trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05009992, a Phase 2 study of Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma, H3 K27M-Mutant, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. This trial will utilize an adaptive platform design in that the different treatment arms for each cohort will be opened and closed based on ongoing preclinical investigation as well as evolving outcome data from the trial. Novel agents will be continuously added to this study as pre-clinical data emerge to suggest additive or synergistic activity when combined ONC201. Should a novel agent not have an RP2D at the time of incorporation into this study, a phase 1 lead-in will be performed prior to initiation of combination therapy (via study amendment).
Primary Outcome
Percentage of participants alive and free from progression at 6 months after the diagnosis. The primary analysis for PFS6 is based on the intention to treat (ITT) population, according to treatment arm assignment. PFS6 is estimated using the Kaplan-Meier method with exact confidence intervals for each cohort and arm. Participants with unknown progression status at 6 months are considered failures (i.e., progressed) for the PFS6 analysis.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Paxalisib
- DRUG ONC201
- DRUG DNX-2401
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California, San Diego / Rady Children's Hospital, San Diego - San Diego
- University of California, San Francisco - San Francisco
Alabama
- University of Alabama at Birmingham - Birmingham
District of Columbia
- Children's National Hospital - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Indiana University Riley Children's Hospital - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Dana-Farber Cancer Institute Harvard University - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
What NCT05009992 shows while recruiting
NCT05009992 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 122-participant average among 28 other Diffuse Intrinsic Pontine Glioma trials with a reported enrollment target (195% higher).
The record links to 6 conditions, with Diffuse Intrinsic Pontine Glioma appearing as the primary indexed condition, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT05009992 names 20 study sites across 18 states, led by California, Alabama, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05009992 about?
NCT05009992 is a clinical study titled "Combination Therapy for the Treatment of Diffuse Midline Gliomas". This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment opti...
What is the current status of trial NCT05009992?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2021-10-20. Estimated completion is 2029-06-30.
What conditions does trial NCT05009992 study?
This clinical trial studies the following conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, WHO Grade III Glioma, Recurrent WHO Grade III Glioma, Recurrent Diffuse Intrinsic Pontine Glioma.
What interventions are being tested in trial NCT05009992?
The interventions under investigation include: Radiation Therapy (RADIATION), Paxalisib (DRUG), ONC201 (DRUG), DNX-2401 (DRUG).
Who is sponsoring clinical trial NCT05009992?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05009992 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Intrinsic Pontine Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05009992's enrollment target sits among peer trials
360 2nd of 28 the highest of 28 other Diffuse Intrinsic Pontine Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Intrinsic Pontine Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Study of Olutasidenib and Temozolomide in HGG
RECRUITING · Phase 2
-
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
ACTIVE NOT RECRUITING · Phase 2
-
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
FUS Etoposide for DMG
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI